Separation and Identification of Isoleucine Enantiomers and Diastereomers Using an Original Chiral Resolution Labeling Reagent
Chemical and Pharmaceutical Bulletin · 01.11.2023 · 71 (11) · 824-831
DOI: 10.1248/cpb.c23-00439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical and Pharmaceutical Bulletin, erschienen am 01.11.2023. Verfasst von Makoto Ozaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Department, Purification Section, Nacalai Tesque, Inc. Hauptthemen laut MEDLINE: Isoleucine, Dinitrobenzenes, Valine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development Department, Purification Section, Nacalai Tesque, Inc.
- Department of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University.
Zitieren
APA
Ozaki, M., Shimotsuma, M., Kuranaga, T., Kakeya, H., & Hirose, T. (2023). Separation and Identification of Isoleucine Enantiomers and Diastereomers Using an Original Chiral Resolution Labeling Reagent. Chemical and Pharmaceutical Bulletin, 71(11), 824-831. https://doi.org/10.1248/cpb.c23-00439
Vancouver
Ozaki M, Shimotsuma M, Kuranaga T, Kakeya H, Hirose T. Separation and Identification of Isoleucine Enantiomers and Diastereomers Using an Original Chiral Resolution Labeling Reagent. Chemical and Pharmaceutical Bulletin. 2023;71(11):824-831. doi:10.1248/cpb.c23-00439
BibTeX
@article{Ozaki2023,
author = {Ozaki, Makoto and Shimotsuma, Motoshi and Kuranaga, Takefumi and Kakeya, Hideaki and Hirose, Tsunehisa},
title = {Separation and Identification of Isoleucine Enantiomers and Diastereomers Using an Original Chiral Resolution Labeling Reagent},
journal = {Chemical and Pharmaceutical Bulletin},
year = {2023},
volume = {71},
number = {11},
pages = {824--831},
doi = {10.1248/cpb.c23-00439}
}
EUVIMED